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Introduction

148
Ex vivo infection of human lymphoid aggregate cultures (HLACs) with HIV-1 is a well-studied model 149 system where HIV-1 induced-inflammasome activation has been characterized (50) (51) (52) (53) (54) (55) and is an appropriate 150 system to study inflammatory signaling that results from HIV-1 infection. Unlike blood-derived CD4-T cells, 151 lymphoid-derived cells are not naturally resistant to pyroptosis in culture and do not require activation or 152 addition of exogenous TLR agonists for HIV-1 infection (51) . Human tonsil explants were obtained from healthy 153 tonsillectomy patients, homogenized as previously described (56) and cultivated in HLACs. HLACs were 154 infected with HIV-1 NL-CI and harvested on 0, 2, 5, 8, and 12 days post infection (DPI) (Figure 2A ). Infection 155 was quantified by flow cytometric detection of mCherry-positive viable cells as indicative of HIV-1 NL-CI 156 infection ( Figure 2B ). Peak infection was noted on Day 8 with a decline by day 12. Infection was statistically 157 significant on days 2-12. Viability of these cells was quantified by flow cytometric detection of live cells ( Figure   158 2C). Viability in the infected condition falls to below 20% by 12 DPI. On 8 DPI, there is a statistically significant 159 difference between viability of infected cells and uninfected cells that corresponds to the timing of peak 160 infection. Figure 2D 165 166 Using this tonsil system that can support HIV-1 infection, we tested whether two P2X antagonists, 167 NF449 (a P2X1>>P2X7 inhibitor) and A438079 (a P2X7 inhibitor) would reduce HIV-1 productive infection in 168 comparison to AZT. HLACs were prepared as in Figure 2 and cells were harvested on 0, 2, 5, 8, and 12 DPI. 169 Viability of these cells was quantified by flow cytometric detection of live cells ( Figure 3A ). As in Figure 2B , 170 viability of cells declined over the infection course by 12 DPI. Interestingly, NF449 and AZT resulted in 171 statistically significant increase cell survival that was most pronounced between 5-12 DPI. Figure 3B indicates 172 infection as measured by quantification of cells with mCherry signal, as indicative of HIV-1 NL-CI productive 173 infection. Both NF449 and A438079 at 100 μM reduce HIV-1 productive infection at all time points from [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] 174 DPI comparable to inhibition seen by AZT. Surprisingly, A438079 (100 μM) effectively inhibited productive HIV-8 1 infection in human tonsil cells on 8 and 12 DPI, although it incompletely inhibited productive infection of 176 PBMCs ( Figure 1A ). Titration of these three drugs was performed at during peak infection at 8 DPI ( Figure 3C 
182
We next tested the supernatants of human tonsil explant tissue blocks to determine how infection levels 183 are associated with secreted cytokines. To do this, tonsils were dissected and cut into small blocks and 184 suspended at the liquid-air interface on collagen rafts. Supernatants were collected on days 2, 5, 8, and 12 DPI 185 ( Figure 4A ) and saved for experimental analysis. Media with drug were changed completely on each indicated 186 DPI, and therefore quantification represents cumulative accumulation of viral production. While HLACs allow 187 for more cellular analysis of viability and infection via flow cytometry, the human tonsil explant tissue block 188 model allows for preservation of the tonsil tissue cytoarchitecture. Given prior evidence that a lymphoid tissue 189 microenvironment is required to support the course of HIV-1 infection and pyroptosis (50, 53, 55) , we pursued 190 the development of a tonsil model that could recapitulate the observations of HIV-1 infection and stimulation of 191 inflammatory cytokine production.
192
First, we attempted to determine if HIV-1 infection and inhibition in the human tonsil explant tissue block 193 model was comparative to the HLAC model. The HIV-1 NL-CI virus expresses an mCherry gene cloned into 194 the nef position and provides and indicator of early viral gene expression. Nef expression is restored with the 195 insertion of an internal ribosome enty site. Therefore, infection was monitored by measurement of viral antigen 196 by HIV-1 p24 ELISA ( Figure 4B ) and by measuring infectivity in the supernatants by exposure to the HIV-1 197 indicator TZM-bl cell line and quantification of relative luminescence units (RLUs) ( Figure 4C ). HIV-1 infection 198 resulted in significant p24 antigen accumulation from 2-12 DPI accompanied by infectivity of the TZM-bl cell 199 lines.
200
We next tested the effect of these drugs on reducing HIV-1 p24 antigen accumulation in the ex vivo 201 tonsil tissue model over the 12-day infection ( Figure 4D ). A significant reduction of HIV-1 p24 antigen 202 accumulation was observed with NF449 (100 μM) treatment on 8 and 12 DPI. As in the HLAC system in Figure   203 9 3, A438079 (100 μM) inhibited HIV-1 p24 antigen accumulation on 8 and 12 DPI. In histoculture, A438079 204 inhibited HIV-1 productive infection to a similar extent as the positive control, AZT (100 μM) that fully blocked 205 productive infection.
207
HIV-1 infection is associated with inflammatory cytokine production in ex vivo lymphoid model 208 209
With confirmation of the establishment of productive infection by HIV-1 in this ex vivo lymphoid model, we 210 next examined if HIV-1 infection stimulated inflammatory cytokine production. Supernatants were harvested 211 from uninfected and infected human tonsil explant tissue blocks and were analyzed for cytokines IL-10, IL-1β, 212 tumor necrosis factor (TNF), interleukin-12p70 (IL-12p70), interleukin-8 (IL-8), and interleukin-6 (IL-6).
213
Supernatants were harvested over the 12-day infection time course and subject to the multiplex bead 214 immunoassay Cytometric Bead Array (CBA; BD Biosciences) ( Figure 5A ). Cumulative measurements indicated 215 that HIV-1 infection stimulated a significant increase in IL-10 and IL-1β from 2 to 12 DPI. HIV-1 infection 216 stimulated a modest but not significant increase of TNF at 12 DPI and did not stimulate an increase in IL-217 12p70, IL-8, or IL-6.
219
We further sought to test whether the stimulation of these cytokines was associated with the magnitude of 220 infection. Figure 5B demonstrates IL-10 and IL-1β production plotted as a function of TZM-bl infectivity. IL-10 221 and IL-1β production are both positively correlated with HIV-1 infection with R 2 values of 0.45 and 0.49,
222
respectively. This suggests that this model can support the stimulation of inflammatory cytokine production that 223 is directly proportional to the level of HIV-1 infection. For the cytokines for which no significant difference was 224 noted in Figure 5A , notably TNF, IL-12, IL-6, and IL-8, no correlation was observed (data not shown).
226
NF449 and A438079 reduce HIV-1 stimulated IL-10 and IL-1β production in human tonsil cells.
228
With the establishment of a tonsil system that supported HIV-1 infection and HIV-1 associated 229 inflammatory cytokine secretion, we examined the role of purinergic signaling pathways in the induction of 230 cytokines by HIV-1 infection. Based on our prior observations that P2X antagonists reduced HIV-1 infection 231 and fusion (34, 57) , it was of interest to test a panel of selective P2X antagonists to identify drugs with 232 inhibition of HIV-1 infectivity in lymphocyte cell lines that would also interfere with HIV-1 stimulation of 233 cytokines in the tonsil system. We tested whether NF449 and A438079 would reduce HIV-1-stimulated 234 inflammatory cytokine production. Human tonsil explant tissue blocks were infected with HIV-1 NL-CI as in 235 Figure 4 . Supernatants from infected human tonsil explant tissue blocks were harvested on 2, 5, 8, and 12 DPI 236 and analyzed for inflammatory cytokines by CBA (BD Biosciences). Cumulative IL-10 and IL-1β production 237 over the 12-day infection course was measured in the presence or absence of indicated antagonists. HIV-1 238 infection stimulated IL-10 production, which was significantly reduced by NF449 and A438079 on 5, 8, and 12 239 DPI ( Figure 6A ). Additionally, HIV-1 infection stimulated IL-1β production, which was significantly reduced by 240 A438079 at 5, 8, and 12 DPI ( Figure 6B ). NF449 did not significantly reduce IL-1β production until 12 DPI. AZT 241 was not expected to inhibit either cytokine production, but did inhibit IL-10 production to a lesser extent than 242 NF449 or A438079. AZT did not reduce IL-1β levels. These observations support the notion that P2X-selective 243 antagonists act on HIV-associated inflammation differently than conventional ART. Overall, we conclude that 244 NF449 and A438079 inhibit HIV-1 replication and IL-10 and IL-1β release in human tonsil explants. This 245 suggests that P2X-selective antagonists are active in both reducing HIV-1 infection and associated 246 inflammation.
248 Discussion
250
Here we demonstrate a human ex vivo tonsil model that can support HIV-1 infection over a 12-day 251 incubation. This model represents an important experimental system to test the signaling that mediates HIV-1 252 infection and HIV-1-stimulated inflammation and illustrates an important distinction between HIV-1 253 inflammation in peripheral blood and in lymphoid tissues. As soluble cytokine production is challenging to 254 measure in PBMCs, it has been necessary for investigators to probe lymphoid tissues for evidence of HIV-1-255 stimulated immune activation and pyroptosis which cannot be demonstrated in peripheral blood (50) (51) (52) (53) (54) (55) . We 256 demonstrate HIV-1 productive infection of human tonsils in HLACs and in human tonsil explant tissue blocks.
257
The advantage to the HLAC system is that cell viability can be measured alongside productive infection using a 258 fluorescent reporter virus. The human tonsil explant tissue blocks allow for measurement of soluble cytokine 259 11 and the measurement of p24 antigen as an indirect measure of HIV-1 spreading infection. Using these two 260 models, we demonstrated HIV-1 replication and HIV-1 stimulated IL-10 and IL-1β production.
262
In the HLAC model, we demonstrated HIV-1 productive infection occurred with a peak at 8 DPI and a 263 corresponding decline in cell viability. All three drugs tested, NF449, A438079, and AZT reduced HIV-1 264 productive infection, while NF449 and AZT resulted in statistically significant increased cell survival, most 265 notably on 8-12 DPI, which likely relates to inhibition of HIV-1 productive infection. Dose dependence inhibition 266 of HIV-1 productive infection was noted for all three drugs with IC 50 values all in the 10-100 μM range.
268
In the human tonsil explant tissue blocks, HIV-1 p24 antigen and TZM-bl infectivity steadily increased over 
274
The P2X-selective antagonists tested, NF449, and A438079, reduced HIV-1-stimulated levels of IL-10 with 275 statistical significance between 5-12 DPI. Treatment with AZT at the corresponding time points resulted in less 276 inhibition of IL-10 compared to the infected condition. This suggests that inflammatory signaling may be 277 blocked not directly through inhibition of productive infection, but through alternative signaling mechanisms.
278
These observations highlight the unique properties of NF449 and A438079 as novel agents that reduce 279 inflammatory changes independent of their antiviral properties.
281
Additionally, the drugs were tested for effect on HIV-stimulated IL-1β production. NF449 reduced HIV-1-282 stimulated levels modestly at 12 DPI whereas A438079 reduced HIV-1-stimulated levels of IL-1β at 8-12 DPI.
283
AZT did not reduce IL-1β levels. Of note, A438079 did not have full inhibition of HIV-1 productive infection in 284 PBMCs, but unexpectedly had strong inhibition of HIV-1 p24 accumulation in human tonsil explants and 285 reduced IL-10 and IL-1β secretion. This surprising observation suggests that the nature of A438079 inhibition 286 of productive infection in tonsils may not be ascribed to a direct link between A438079 and HIV-1 entry, but 287 rather through cytokine-dependent signaling. There are several possible explanations for this phenomenon.
288
The immunomodulatory role of IL-10 may serve to enhance HIV-1 permissively, but when levels of IL-10 are 289 reduced by A438079, cells may be more susceptible to A438079 inhibition of HIV-1 infection. Tonsil tissue 290 represents mixed cellular populations with stromal compartments with altered sensitivity to P2X inhibition as 291 compared to PBMCs (58) (59) (60) . It will be of interest to explore the cell-type heterogeneity of HIV-1 infection in 292 tonsils to determine the cell type and signaling mechanisms that drive IL-10 and IL-1β production. These 293 directions may lead to the development novel therapeutic agents that retain inhibition of spreading HIV-1 294 infection and can reduce HIV-1 stimulated levels of IL-10 and IL-1β.
296
The role of P2X receptors in HIV-1 pathogenesis likely relate to downstream activation of the NLRP3 297 inflammasome. The NLRP3 activates immature caspase-1 to activated caspase-1, which cleaves and activates 298 pro-IL-1β. These cytokines, among others, play a pivotal role in signaling of other inflammatory cytokines.
299
Emerging evidence suggests a key role for the inflammasome in atherosclerotic disease progression (61) (62) (63) 300 (64) (65) (66) (67) (68) (69) (70) (71) and in HIV-1 disease (46, (72) (73) (74) (75) (76) (77) . Inflammasome activation requires two signals, one for priming (i.e.
301
TLR signaling which results in transcriptional regulation), and then activation for inflammasome complex 302 assembly. Together with TLR signaling, P2X7 can signal inflammasome activation and subsequent IL-1β 303 release (78) . As the tonsil tissue contains soluble factors that likely include TLR agonists, inflammasome 304 activation is readily measurable with second signal stimulation, i.e. P2X7 activation by HIV-1 infection. HIV-1 305 infected patients have elevated circulating levels of LPS, which can serve to increase transcriptional activation 306 of pro-inflammatory cytokines (11, 49) . Elevated levels of IL-1β are associated with many of the AANCCs seen 307 in HIV-1 infected patients (79) (80) (81) (82) . Currently, there are multiple clinical trials assessing the safety and efficacy 308 of anti-IL-1β antibodies in cardiovascular disease (83, 84) . Canakinumab, a human monoclonal IL-1β antibody, 309 has been shown to significantly decrease arterial inflammation in HIV-1 infected individuals (85). The role of 310 P2X receptors in the secretion of IL-1β may represent a key mechanism for HIV-1 associated inflammation.
311
Elevated IL-1β is observed in HIV-1 infected patients (76, (86) (87) (88) and an emerging literature implicates the role 312 of IL-1β in atherosclerotic cardiovascular disease in both HIV-1 infected and uninfected patients (83-85).
313
Intriguing studies in CD4 + T cells find that pathogen sensor interferon-γ-inducible protein 16 (IFI-16) recognition 314 13 of HIV-1 DNA can activate the NLRP3 inflammasome that induces pyroptosis and may represent a mechanism 315 for CD4 + T cell depletion in HIV-1 disease and progression to advanced disease (53) (54) (55) .
317
The fact that both IL-10 and IL-1β were together stimulated by HIV-1 infection and reduced by NF449 and 318 A438079 are surprising, given that they have opposing inflammatory effects. IL-10 is an immunomodulatory 319 cytokine with immunosuppressive activities and has been implicated in immune exhaustion and cell death 320 through inhibition of NF-kB activity (89-93). IL-10 activation has been linked to P2X7 signaling with the 321 observation of down-modulation of IL-10 receptor expression with P2X7 activation (94). IL-10 has the potential 322 to impact many areas of HIV-1 infection including CD4 function, chemokine receptor expression, and 323 modulation of replication (95-97). IL-10 gene polymorphisms and epigenetics have been shown to be 324 associated with variations in HIV-1 transmission and disease progression, as long-term non-progressors 325 (LTNP) have low IL-10 levels compared with HIV-1 progressors (98) (99) (100) (101) (102) (103) . This suggests that IL-10 may be 326 important for modulating the immune response to HIV-1 infection and the high levels of HIV-1-stimulation may 327 account for the relatively low levels of induction of other pro-inflammatory cytokines such as IL-6 and TNF.
328
Further studies are needed to understand the role of IL-10 in HIV-1 disease progression and inflammation, and 329 P2X-selective antagonists may play a role in developing novel therapeutics that target both HIV-1 infection and 330 inhibition of IL-10 signaling. Figure 7A summarizes the observations of HIV-1 infection and inflammatory cytokine production in both 333 PMBCs and tonsils. While all drugs inhibit HIV-1 infection, A438079 had the least effect on inhibition of HIV-1 334 infection. It should be noted that IL-10 and IL-1β stimulation were not observed in this system. Since it was not 335 possible to demonstrate HIV-1 specific stimulation of inflammatory cytokines in this model, it was necessary to 336 establish a lymphoid model that would more accurately recapitulate inflammatory cytokine signaling. In the 337 tonsil model, all three drugs inhibited HIV-1 infection to a comparable magnitude in HLACs, while A438079 and 338 AZT inhibited p24 accumulation more than NF449. By comparison, NF449 and A438079 inhibited IL-10 339 production most strongly while AZT only modestly reduced IL-10 production. Finally, NF449 and A438079 340 inhibited IL-1β production modestly while AZT did not inhibit IL-1β production.
332
342 14
Taken together, we propose the model in Figure 7B , in which P2X-selective antagonists play a role in 343 inhibiting both HIV-1 infection and HIV-1-stimulated inflammation. The model indicates that NF449 and 344 A438079 may have different mechanisms of action on HIV-1 entry and inflammation. Stimulation of 345 inflammatory signaling by P2X7 and TLR4 results in NLRP3-dependent production of IL-1β as well as NF-kB-346 dependent regulation of IL-10. NF449 inhibits this inflammation and HIV-1 productive infection in both PBMCs 347 and tonsil cells, suggesting that the inhibition is not dependent on intact inflammasome signaling, but may act 348 more directly on HIV-1 entry mechanisms. By contrast, A438079 inhibits HIV-1 productive infection that is 349 limited to the tonsil system, indicating that this inhibition is dependent on intact NLRP3 signaling mechanisms 350 that are not activated in PBMCs. The role of cytokine signaling in permissivity to HIV-1 infection in mixed cell 351 populations is an important area of future investigation as the tonsil tissue model system is important in 352 understanding the interplay between HIV-1 pathogenesis and the immune response.
354
Here we demonstrate that P2X-selective antagonists have the potential to reduce HIV-1 infection and HIV-355 1-stimulated inflammatory cytokine production. We conclude from these studies that P2X-selective antagonists 356 may represent potential HIV-1 therapeutic options that serve to inhibit HIV-1 replication and innate immune 357 sensing. Further studies will be necessary to identify selective inhibitors that are amenable to pharmacologic 358 development and the precise mechanism of their inhibition, but these observations introduce important 359 prospects for dually active therapeutic options that would reduce the burden of morbidity and mortality of 360 chronic inflammation in HIV-1-infected individuals. 361 362 Virus production. HIV-1 NL-CI contains mCherry in place of nef, and nef expression is directed by a 364 downstream internal ribosome entry site (IRES) (44) . Pseudoviruses were produced by co-transfecting 365 293T/17 cells with HIV-1 rev-and env-expressing plasmids and the pNL4-3Δenv R-E-plasmid using the jetPEI 366 transfection reagent (Polyplus-transfect SA). Supernatants were harvested after 48 hours and clarified by high-367 speed centrifugation (Sorvall ST 40R Centrifuge, Thermo Fisher Scientific) at 100,000 x g at 4°C for 2 hours 368 and 0.45 μm filtration. Single-use aliquots were stored at −80°C. Viral stocks were quantified via enzyme-linked 369 immunosorbent assay (ELISA), as described below. HIV-1 MN (X4-tropic) was produced at the AIDS Vaccine
370
Program, National Cancer Institute as previously described (104) (105) (106) . by Ficoll density-gradient centrifugation, as previously described (51) . Cells were plated at 2.5 x 10 5 cells/well 390 in a round-bottom 96-well plate (Costar) and spun down at 500 x g for 3 minutes every 2-3 days to replace 391 media with our without indicated inhibitor. Human tonsil explant tissue blocks and HLACs were maintained in 392 RPMI 1640 medium (Life Technologies) containing 15% FBS, 2 mM GlutaMAX (Life Technologies), 2 mM L-393 glutamine (Corning), 1 mM sodium pyruvate (Corning), 1% MEM non-essential amino acids (Corning), 2.5 394 μg/mL Amphotericin B (HyClone), 50 mg/mL gentamicin sulfate (Corning), and 0.3 mg/ml Timentin 395 (bioWORLD).
397
Antagonists. Inhibitors were tested for the ability to block HIV-1 infection and HIV-1 associated inflammation 398 at 100 μM, unless otherwise stated. These include NF449 (Tocris), a P2X1 selective antagonist, A438079 399 (Tocris), a P2X7 selective antagonist, and the reverse transcriptase inhibitor azidothioidine (AZT; Sigma).
400
NF449 and A438079 were diluted from 10 mM stocks reconstituted in DMSO while AZT was diluted from 10 401 mM stocks reconstituted in water. 
419
Productive infection in PBMCs. PBMCs were activated with PHA (4 μg/ml) and IL-2 (50 U/mL) for 3 days 420 and infected by spinoculation, as previously described (107, 108) . Briefly, 2.5 x 10 5 cells were incubated in the 421 presence or absence of indicated inhibitors in a 96-well flat bottom plate for 30 minutes at 37C then spun at 422 1,200 x g for 99 minutes with 47.7 ng HIV-1 NL-CI. After overnight incubation at 37C, the culture medium was 423 replaced with complete RPMI containing IL-2 (50 U/ml) and 10 M AZT. At 48 h after spinoculation, cells were 424 stained and fixed in 2% paraformaldehyde for flow cytometry, as described above.
426
Ex vivo infection of human tonsil explant tissue blocks and HLACs. Human tonsil explant tissue blocks 427 from each donor were individually inoculated with 5 µl of HIV-1 NL-CI (equivalent to 3.24 ng p24),or left 428 uninfected in the presence or absence of indicated inhibitors. We measured HIV-1 p24 antigen in harvested 429 supernatants and infectivity in relative RLUs by TZM-bl assay as described below, as the NL-CI fluorophore 430 can only be detected in cell-based systems. Data are expressed as a cumulative value to account for total 431 successive media changes. For HLAC experiments, cells were incubated in the presence or absence of 432 indicated inhibitors for 30 minutes at 37C before infection with 25 ng HIV-1 NL-CI p24 per well. Cells were 433 stained and fixed for flow cytometry, as described above. 434 435 p24 ELISA. Viral stocks and tonsil tissue supernatants were quantified via ELISA with coating antibody D7320, 436 sheep anti-HIV-1-p24 gag (Aalto Bio Reagents), as previously described (57, 109 
443
18 444 TZM-bl HIV-1 infectivity assay. Virus infectivity of supernatants collected from tonsil was measured using a 445 β-galactosidase-based luciferase assay (Promega) with TZM-bl target cells, as previously described (110) .
446
Briefly, TZM-bl cells were plated at 1.5 X 10 
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Data represent cumulative cytokine production by summing the measurements at each successive time point.
869
Mean values ± SEM are represented from six donors *, p ≤ 0.05, **, p ≤ 0.01, ***, p ≤ 0.001. inflammasome. This pathway is activated in concert with TLR4 receptor activation which can drive caspase-1 875 to cleave pro-IL-1β to mature IL-1β. Mature IL-1β can be secreted or induce pyroptosis in CD4 + T-cells. This 876 signaling can also activate NF-kB dependent transcriptional regulation of IL-10. Inhibition of this mechanism by 877 NF449 may explain enhanced cell survival in tonsil cells. A438079, by contrast, may act directly on P2X7 to 878 inhibit receptor signaling that is required for HIV-1 entry. P2X7 inhibition results in the inability to activate the 879 NLRP3 inflammasome and pyroptosis in tonsil cells, which does not occur in PBMCs. Therefore, A438079 880 depends on intact inflammasome signaling to exert inhibition on HIV-1 productive infection. 
